A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Cervical Cancer (CC) Failed or Intolerance to Standard First-Line Therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

25 Feb 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 14 Feb 2025 to 20 Feb 2025.
25 Feb 2025 Status changed from not yet recruiting to recruiting.
16 Jan 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com